Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03867253 · ClinicalTrials.gov registry record · Phase 2
Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by Oryzon Genomics S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT03867253: Completed Phase 2 study, sponsored by Oryzon Genomics S.A..
NCT03867253 is a Phase 2 study that has completed, run by Oryzon Genomics S.A.. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03867253, a Phase 2 study, has completed, sponsored by Oryzon Genomics S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a Phase IIa study assessing the safety, tolerability and preliminary efficacy of ORY-2001 in mild to moderate Alzheimer's Disease patients.
Primary Outcome
Number, frequency and severity of Treatment Emergent Adverse Events (TEAEs) including serious TEAEs.
Interventions
- DRUG Placebo
- DRUG ORY-2001 Low dose
- DRUG ORY-2001 High dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-05-16 |
| Est. Completion | 2020-11-12 |
| Phase | Phase 2 |
What the finished NCT03867253 record still lists
NCT03867253 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03867253 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03867253 about?
NCT03867253 is a clinical study titled "Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease". This is a Phase IIa study assessing the safety, tolerability and preliminary efficacy of ORY-2001 in mild to moderate Alzheimer's Disease patients.
What is the current status of trial NCT03867253?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2019-05-16. Estimated completion is 2020-11-12.
What interventions are being tested in trial NCT03867253?
The interventions under investigation include: Placebo (DRUG), ORY-2001 Low dose (DRUG), ORY-2001 High dose (DRUG).
Who is sponsoring clinical trial NCT03867253?
This trial is sponsored by Oryzon Genomics S.A., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03867253's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI